CNS Pharmaceuticals, Inc. (CNSP:NASDAQ) Annual Reports & Investor Relations Material

Overview

CNS Pharmaceuticals, a Houston-based clinical pharmaceutical firm, is focused on the development of novel anti-cancer drug candidates targeting central nervous system tumors. Their lead candidate, Berubicin, has successfully completed Phase I clinical trials and is designed for the treatment of glioblastoma multiforme. CNS has struck license agreements with Houston Pharmaceuticals and The University of Texas M.D. Anderson Cancer Center, alongside a development agreement with WPD Pharmaceuticals Inc. Founded in 2017, the company is committed to the advancement of cancer care through cutting-edge pharmaceutical solutions.

Annual Reports

Frequently Asked Questions

What is CNS Pharmaceuticals, Inc.'s ticker?

CNS Pharmaceuticals, Inc.'s ticker is CNSP

What exchange is CNS Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are CNS Pharmaceuticals, Inc.'s headquarters?

They are based in Houston, Texas

How many employees does CNS Pharmaceuticals, Inc. have?

There are 1-10 employees working at CNS Pharmaceuticals, Inc.

What is CNS Pharmaceuticals, Inc.'s website?

It is https://cnspharma.com/

What type of sector is CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is in the Biotechnology industry

Who are CNS Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are CNS Pharmaceuticals, Inc.'s industry peers:

- Allakos Inc.

- UroGen Pharma Ltd.

- Jounce Therapeutics

- Oncternal Therapeutics, Inc.

- I-MAB